298 related articles for article (PubMed ID: 19808642)
1. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
Chung ES; Chauhan SK; Jin Y; Nakao S; Hafezi-Moghadam A; van Rooijen N; Zhang Q; Chen L; Dana R
Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
3. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
5. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
7. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.
Tammela T; Zarkada G; Nurmi H; Jakobsson L; Heinolainen K; Tvorogov D; Zheng W; Franco CA; Murtomäki A; Aranda E; Miura N; Ylä-Herttuala S; Fruttiger M; Mäkinen T; Eichmann A; Pollard JW; Gerhardt H; Alitalo K
Nat Cell Biol; 2011 Sep; 13(10):1202-13. PubMed ID: 21909098
[TBL] [Abstract][Full Text] [Related]
8. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
[TBL] [Abstract][Full Text] [Related]
10. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
11. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.
Flister MJ; Wilber A; Hall KL; Iwata C; Miyazono K; Nisato RE; Pepper MS; Zawieja DC; Ran S
Blood; 2010 Jan; 115(2):418-29. PubMed ID: 19901262
[TBL] [Abstract][Full Text] [Related]
12. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan-induced VEGF-C promotes fibrosis-induced lymphangiogenesis via Toll-like receptor 4-dependent signal pathway.
Jung YJ; Lee AS; Nguyen-Thanh T; Kang KP; Lee S; Jang KY; Kim MK; Kim SH; Park SK; Kim W
Biochem Biophys Res Commun; 2015 Oct; 466(3):339-45. PubMed ID: 26362177
[TBL] [Abstract][Full Text] [Related]
15. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
[TBL] [Abstract][Full Text] [Related]
16. Lymphangiogenesis-independent resolution of experimental edema.
Ongstad EL; Bouta EM; Roberts JE; Uzarski JS; Gibbs SE; Sabel MS; Cimmino VM; Roberts MA; Goldman J
Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H46-54. PubMed ID: 20207821
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
18. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
Wuest TR; Carr DJ
J Exp Med; 2010 Jan; 207(1):101-15. PubMed ID: 20026662
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
Jenny B; Harrison JA; Baetens D; Tille JC; Burkhardt K; Mottaz H; Kiss JZ; Dietrich PY; De Tribolet N; Pizzolato GP; Pepper MS
J Pathol; 2006 May; 209(1):34-43. PubMed ID: 16523449
[TBL] [Abstract][Full Text] [Related]
20. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
Hos D; Regenfuss B; Bock F; Onderka J; Cursiefen C
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5778-85. PubMed ID: 21666240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
